Objectives: Community-acquired pneumonia (CAP) in children is one of the most important causes of mortality and morbidity in developing countries. Therefore, it is very important for clinicians to detect the presence and severity of pneumonia. Proadrenomedullin (Pro-ADM) and Interleukin-1β (IL-1β) are thought to have potential for CAP evaluation in children. We sought to investigate the value of Pro-ADM and IL-1β levels for severity assessment and outcome prediction in children with CAP.

Methods: A total of 66 hospitalized CAP patients were included in a prospective observational study. Complete blood count, serum C-reactive protein (CRP), Pro-ADM and IL-1β levels were studied in blood samples obtained from the patients upon admission. Respiratory Clinical Score (RCS) was performed to determine the respiratory distress and severity.

Results: The comparison of data with laboratory-severity groups: serum CRP, Pro-ADM and IL-1β levels increased in parallel with the disease severity. Pro-ADM was the best biomarker for severity stratification. Logistic regression analysis revealed that RCS >6 points and Pro-ADM values >1.75 nmol/L combination had the most significant results (OR: 15.38, 95% CI 1.35-166.66, =0.027). Moreover, a relationship was found between the high serum levels of IL-1β and requirement of intervention procedures in patients with pleural effusion.

Conclusions: Serum Pro-ADM and IL-1β levels may offer additional risk/severity stratification in children with CAP. In addition, they may be helpful in predicting the development of complications, requirements for ntensive care unit admission, and intervention procedures.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pro-adm il-1β
16
il-1β levels
16
community-acquired pneumonia
8
crp pro-adm
8
intervention procedures
8
pro-adm
7
il-1β
6
severity
5
levels
5
reliability pro-adrenomedullin
4

Similar Publications

Objective: Adrenomedullin (ADM) is a potent vasodilator. The association between plasma ADM levels and blood pressure (BP) remains unclear. We assessed the association between mid-regional-pro-ADM (MR-proADM) and BP in a multicenter population- and family-based cohort.

View Article and Find Full Text PDF

A growing body of evidence indicates there is an increasing incidence of cognitive dysfunction in patients after coronavirus disease 2019 (COVID-19) infection. However, still lack diagnostic tools, which allow us to predict prognosis in such cases and improve the stratification of the disease. This study aims to evaluate the usefulness of the biomarkers that could allow to predict the severity and progression of COVID-19 in patients with post-COVID syndrome and cognitive problems.

View Article and Find Full Text PDF

Background: Several studies have examined the potential of adrenomedullin (ADM), pro-adrenomedullin (Pro-ADM), and mid-regional-pro-ADM (MR-Pro-ADM) as biomarkers for diagnosing and assessing the severity of heart failure (HF), with conflicting results. We aimed to investigate their diagnostic utility and their correlation with HF severity based on the New York Heart Association (NYHA) classification.

Methods: We searched PubMed, EMBASE, and Scopus using a predefined search string.

View Article and Find Full Text PDF
Article Synopsis
  • Congestion significantly impacts outcomes in acute heart failure, and assessing it can be complicated, making effective treatment difficult; residual congestion at discharge increases risks of re-hospitalization and mortality.
  • A study involving 233 patients with acute heart failure assessed the link between pro-adrenomedullin levels and congestion as well as clinical outcomes like in-hospital death and post-discharge mortality, revealing that higher pro-adrenomedullin levels are tied to worse outcomes.
  • Findings suggest that monitoring pro-adrenomedullin can serve as a useful marker for evaluating congestion and guiding therapies in acute heart failure patients, with elevated levels correlating with heightened risk of worsening heart failure and death post-discharge.
View Article and Find Full Text PDF

The role of inflammation and antithrombin supplementation on thromboelastographic parameters during veno-venous ECMO for respiratory failure.

Perfusion

April 2024

Department of Anesthesiology, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Introduction: Extracorporeal membrane oxygenation (ECMO) may act as a driver or propagator of systemic inflammation. In turn, cytokine release can modify thromboelastographic (TEG) tests which are commonly used for anticoagulation monitoring. In this context, antithrombin (AT) supplementation might further modify TEG.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!